RIPK1-IN-42
RIPK1-IN-42 is an orally active RIPK1 inhibitor with a Kd of 21 nM. RIPK1-IN-42 inhibits the phosphorylation of RIPK1, suppresses the phosphorylation of downstream RIPK3 and MLKL, blocks necrosome formation, and inhibits necroptosis. RIPK1-IN-42 alleviates hypothermia, suppresses the elevation of pro-inflammatory cytokine levels, and reduces organ damage. RIPK1-IN-42 can be used for the research of systemic inflammatory response syndrome.
For research use only. We do not sell to patients.
- Formula: C23H18F2N2O3
- Molecular Weight:408.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
RIPK1 21 nM (Kd) |
RIPK3 |
In Vitro
RIPK1-IN-42 (Compound W-1) (0.002441-0.3125 μM; 6 h) potently inhibits necroptosis in HT-29 cells induced by TNF-α, SM-164 (HY-15989) and Z-VAD-FMK (HY-16658B) (TSZ), with an EC50 of 38.46 nM[1].
RIPK1-IN-42 (0.1-12.8 μM; 14 h) effectively inhibits TNF-α-, Cycloheximide (HY-12320)- and Z-VAD-FMK (TCZ)-induced necroptosis in HT-29 cells in vitro in a dose-dependent manner[1].
RIPK1-IN-42 (4.6875-600 nM; 10 h) effectively inhibits TSZ-induced necroptosis in U937 cells in vitro in a dose-dependent manner[1].
RIPK1-IN-42 (6.25-400 nM; 2-6 h) inhibits TSZ-induced phosphorylation of RIPK1, RIPK3 and MLKL in HT-29 cells in a time- and dose-dependent manner[1].
RIPK1-IN-42 (400 nM; 6 h) blocks TSZ-induced necrosome formation in HT-29 cells[1].
RIPK1-IN-42 (24 h) does not inhibit cycloheximide-induced apoptosis in HT-29 cells[1].
RIPK1-IN-42 exhibits low cytotoxicity in HT-29 cells, with a CC50 greater than 100 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT-29 cells
-
Concentration:400 nM (time-course); 6.25, 25, 100 and 400 nM (dose-dependent)
-
Incubation Time:2, 4 and 6 h (time-course); 5 h (dose-dependent)
-
Result:Suppressed phosphorylation of RIPK1, RIPK3, and MLKL within 2 to 6 hours of TSZ treatment at 400 nM.
Inhibited phosphorylation of RIPK1, RIPK3, and MLKL in a dose-responsive manner across 6.25-400 nM after 5 hours of TSZ treatment.
-
Cell Line:HT-29 cells
-
Concentration:400 nM
-
Incubation Time:6 h
-
Result:Reduced co-immunoprecipitation of RIPK3 with RIPK1 compared to TSZ-only treatment.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (female)[1]
-
Dosage:10 mg/kg; 20 mg/kg; 30 mg/kg
-
Administration:p.o.; single dose 1 hour pre-challenge
-
Result:Attenuated mTNF-α/Z-VAD-FMK-induced hypothermia, with body temperatures gradually restoring to normal levels over 9 hours across all tested doses.
Achieved 40% survival at 10 mg/kg, 60% survival at 20 mg/kg, and 90% survival at 30 mg/kg.
Significantly suppressed serum elevation of pro-inflammatory cytokine interleukin-6 (mIL-6) induced by TNFα challenge.
Reduced serum levels of organ damage biomarkers (lactate dehydrogenase, aspartate aminotransferase, creatinine, blood urea nitrogen) to levels closer to healthy animals.
Attenuated histologic signs of injury (inflammatory cell infiltration, tissue disorganization, cellular damage) in the heart, liver, and kidneys.
Chemical Information
-
Molecular Weight 408.40
-
Formula C23H18F2N2O3
-
SMILES
CN1C2=C(C=CC=C2)OC[C@H](NC(C3=CC(C4=CC(F)=CC=C4F)=CC=C3)=O)C1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)